| 宋玉华彭鹏△ 邱少敏王清波谈国蕾.急性髓细胞性白血病（AML）中IL-3Rα 基因的表达及意义[J].现代生物医学进展英文版,2012,12(19):3632-3634. |
| 急性髓细胞性白血病（AML）中IL-3Rα 基因的表达及意义 |
| Expression of IL-3Rα in Acute Myeloid Leukemia(AML) and its Significance |
| |
| DOI： |
| 中文关键词: 白介素-3 受体α 亚基（IL-3Rα） 急性髓细胞性白血病 |
| 英文关键词: The interleukin-3 receptor α chain(IL-3Rα) Acute myeloid leukemia(AML) |
| 基金项目: |
|
| Hits: 961 |
| Download times: 786 |
| 中文摘要: |
| 目的：检测白介素-3 受体α 亚基（IL-3Rα）在急性髓细胞性白血病（acute myeloid leukemia，AML）中的表达，研究其在AML
发病和预后评估中的意义。方法：应用逆转录- 聚合酶链反应（RT-PCR）法检测57 例AML 患者IL-3Rα 的表达，其中包括52 例
初治和复发患者（6 例M1、28 例M2、10 例M3、3 例M4、5 例M5）及5 例缓解患者，另10 例正常人作为对照。结果：①10 例正常
人和5 例AML 缓解患者未检测到IL-3Rα 表达。②52 例初治和复发的AML 患者中IL-3Rα 阳性表达21 例，占40.38%，M1～M5
各型患者的阳性率差异无显著性（P＞0.05）。初治和复发AML 患者之间IL-3Rα 阳性表达无明显差异（P＞0.05）。③AML 患者的
IL-3Rα 阳性表达与外周血白细胞计数、骨髓中原始细胞比例、CD34 阳性表达有关（P＜0.05）。④AML 患者中IL-3Rα 阳性表达的
患者CR 率低于阴性者（P＜0.05）。结论：①IL-3Rα 在AML 发病中有一定作用。②IL-3Rα 基因可作为AML 预后不良的一个指
标。 |
| 英文摘要: |
| Objective: To investigate the expression and significance of IL-3R α in 57 paitients with acute myeloid leukemia
(AML). Methods: RT-PCR method was perfomed to examine the expression of IL-3Rα in bone marrow or peripheral blood
mononuclear cells from 57 paitients with AML. The paitients included 52 newly diagnosed and relapse paitients (6 M1, 28 M2, 10 M3, 3
M4, 5 M5) and 5 CR patients. 10 healthy subjects were used as control group. Results: ①5 CR patients didn't express IL-3Rα mRNA.②
The percentage of IL-3Rα mRNA expression in AML was 40.38%. IL-3Rα mRNA was expressed in all AML subtypes, and there was no
difference among AML subtypes. In AML paitients, there was no difference between newly diagnosed and relapse patients. ③In AML
patients, the expression of IL-3Rα mRNA related to white blood count, blast cells ratio and CD34 positive expression(P<0.05).④The CR
rate of AML patients who expressed IL-3Rα was significantiy lower than that of who didn't express IL-3Rα (P<0.05). Conclusions: ①
IL-3Rα gene might play an important role in the pathogenesis of AML.②IL-3Rα gene may be a poor prognostic factor in AML. |
|
View Full Text
View/Add Comment Download reader |
| Close |
